Researchers at New York University Grossman School of Medicine, led by Erin E. Congdon, have explored the potential of single-domain antibodies (sdAbs) in treating tauopathies, including Alzheimer’s disease. The results of their study were recently published in The Lancet® and focused
Single Domain Antibodies (aka Nanobodies, VHH antibodies & camelid antibodies) are at the forefront of research in HIV, cancer, & other cell diseases.
The single-domain antibodies (sdAb), lack light chains, yet possess unique characteristics providing researchers a myriad of options not readily available with conventional antibodies. In comparison, the sdAbs boast significantly higher stability and are much smaller in size, only 15kd. As
The PD-1 protein is a negative co-stimulatory receptor that can bind two different but related ligands, PD-L1 and PD-L2. Upon binding, signals generated by PD-1 inhibit the activation of the immune response in the absence of “danger signals.” ProSci Inc.
Though the adaptive immune system functions similarly across most vertebrates, some species such as bovine, camelids, and sharks stand out from the others with unique antibodies that only occur in their own evolutionary path. These antibodies have characteristics that can
Antibodies are characterized by versatility in form and in function: they are great communicators in the immune system, they can be used to visualize obscure targets, and can stabilize otherwise transient molecular states. In 2011, Brian K. Kolbilka and Robert
Llamas make especially tiny antibodies that can neutralize 60 strains of HIV. Known for being sturdy and dependable animals, leave it to llamas to deliver some good news in the slow-going quest for an HIV vaccine. (learn more about ProSci’s